• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Panbela Therapeutics Inc.

    1/30/23 4:38:38 PM ET
    $PBLA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PBLA alert in real time by email
    SC 13G 1 sched13g.htm





     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     

     
    SCHEDULE 13G
     
     
     
    Under the Securities Exchange Act of 1934
     
     
     
    (Amendment No.   )*
     

     
    PANBELA THERAPEUTICS, INC.
     
     
    (Name of Issuer)
     

     
    Common Stock, par value $0.001 per share
     
     
    (Title of Class of Securities)
     

     
    69833W206
     
     
    (CUSIP Number)
     

     
    January 30, 2023
     
     
    (Date of Event which Requires Filing of this Statement)
     


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    [ ]            Rule 13d-1(b)
    [x]            Rule 13d-1(c)
    [ ]            Rule 13d-1(d)
    ___________________________________
    *  The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


     
    1
     
    Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons (entities only)
    Lind Global Fund II LP
     
     
    2
     
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
     
    (a)            [ ]
     
     
    (b)            [x]
     
    3
     
    SEC Use Only
     
    4
     
    Citizenship or Place of Organization.
     
    Delaware
     

     
    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
     
    5  Sole Voting Power
    590,000
     
    6  Shared Voting Power
     
    0
     
    7  Sole Dispositive Power
     
    590,000
     
    8  Shared Dispositive Power
     
    0

     
    9
     
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    590,000(1)
     
     
    10
     
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
     
     
     
    11
     
    Percent of Class Represented by Amount in Row (9)*
     
    9.9%(2)
     
     
    12
     
    Type of Reporting Person (See Instructions)
    PN
     
    (1) The reporting person’s ownership consists of (i) 325,000 shares of common stock and (ii) 650,000 warrants to purchase shares of common stock (“Warrants”); however, due to the exercise limitations of the Warrants, the reporting person’s beneficial ownership of 385,000 Warrants is excluded.
    (2) Each of the Warrants includes a provision limiting the holder’s ability to exercise the Warrants if such exercise would cause the holder to beneficially own greater than 9.99% of the Company.




     
    1
     
    Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons (entities only)
    Lind Global Partners II LLC
     
     
    2
     
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
     
    (a)            [ ]
     
     
    (b)            [x]
     
    3
     
    SEC Use Only
     
    4
     
    Citizenship or Place of Organization.
     
    Delaware
     

     
    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
     
    5  Sole Voting Power
     
    590,000
     
    6  Shared Voting Power
     
    0
     
    7  Sole Dispositive Power
     
    590,000
     
    8  Shared Dispositive Power
     
    0

     
    9
     
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    590,000(1)
     
     
    10
     
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
     
     
     
    11
     
    Percent of Class Represented by Amount in Row (9)*
     
    9.9%(2)
     
     
    12
     
    Type of Reporting Person (See Instructions)
    OO
     
    (1) The reporting person’s ownership consists of (i) 325,000 shares of common stock and (ii) 650,000 Warrants; however, due to the exercise limitations of the Warrants, the reporting person’s beneficial ownership of 385,000 Warrants is excluded.
    (2) Each of the Warrants includes a provision limiting the holder’s ability to exercise the Warrants if such exercise would cause the holder to beneficially own greater than 9.99% of the Company.


     
    1
     
    Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons (entities only)
     
    Jeff Easton
     
    2
     
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
     
    (a)            [ ]
     
     
    (b)            [x]
     
    3
     
    SEC Use Only
     
    4
     
    Citizenship or Place of Organization.
     
    United States
     

     
    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
     
    5  Sole Voting Power
     
    590,000
     
    6  Shared Voting Power
     
    0
     
    7  Sole Dispositive Power
     
    590,000
     
    8  Shared Dispositive Power
     
    0

     
    9
     
    Aggregate Amount Beneficially Owned by Each Reporting Person
    590,000(1)
     
     
    10
     
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
     
     
     
    11
     
    Percent of Class Represented by Amount in Row (9)*
     
    9.9%(2)
     
     
    12
     
    Type of Reporting Person (See Instructions)
     
    IN
     
     
    (1) The reporting person’s ownership consists of (i) 325,000 shares of common stock and (ii) 650,000 Warrants; however, due to the exercise limitations of the Warrants, the reporting person’s beneficial ownership of 385,000 Warrants is excluded.
    (2) Each of the Warrants includes a provision limiting the holder’s ability to exercise the Warrants if such exercise would cause the holder to beneficially own greater than 9.99% of the Company.




    Item 1.
    (a)
    Name of Issuer
     
     
    Panbela Therapeutics, Inc.
    (b)
    Address of Issuer’s Principal Executive Offices
     
     
    712 Vista Blvd., #305
    Waconia, MN 55387
     

    Item 2.
    (a)
    Name of Person Filing
     
     
    This statement is filed by the following entities and individuals (collectively, referred to as the “Reporting Persons”):
     
    •   Lind Global Fund II LP, a Delaware limited partnership;
    •   Lind Global Partners II LLC, a Delaware limited liability company; and
    •   Jeff Easton, an individual and a citizen of the United States of America.
     
    Lind Global Partners II LLC, the general partner of Lind Global Fund II LP, may be deemed to have sole voting and dispositive power with respect to the shares held by Lind Global Fund II LP.
     
    Jeff Easton, the managing member of Lind Global Partners II LLC, may be deemed to have sole voting and dispositive power with respect to the shares held by Lind Global Fund II LP.
     
    (b)
    Address of Principal Business Office or, if none, Residence
     
     
    The address of the principal business office for each of the Reporting Persons is:
     
    444 Madison Ave, Floor 41
    New York, NY 10022
     
    (c)
    Citizenship
     
     
    See Row 4 of cover page for each Reporting Person.
     
    (d)
    Title of Class of Securities
     
     
    Common Stock, par value $0.001 per share
    (e)
    CUSIP Number
     
     
    69833W206
    Item 3.
    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    Not applicable.
    Item 4.
    Ownership
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
    (a)
    Amount Beneficially Owned
     
     
     See Row 9 of cover page for each Reporting Person.
     
    (b)
    Percent of Class
     
     
    See Row 11 of cover page for each Reporting Person.
     

    (c)
    Number of shares as to which such person has:
     
     
    (i)
    sole power to vote or to direct the vote
       

    See Row 5 of cover page for each Reporting Person.
     
     
    (ii)
    shared power to vote or to direct the vote
       
     
    See Row 6 of cover page for each Reporting Person.
     
     
    (iii)
    sole power to dispose or to direct the disposition of
       

    See Row 7 of cover page for each Reporting Person.
     
     
    (iv)
    shared power to dispose or to direct the disposition of
       
     
    See Row 8 of cover page for each Reporting Person.
     

    Item 5.  Ownership of Five Percent or Less of a Class
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.
    Item 6.  Ownership of More than Five Percent on Behalf of Another Person
    Not applicable.
    Item 7.  Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company
    Not applicable.
    Item 8.
    Identification and Classification of Members of the Group
    Not applicable.
    Item 9.
    Notice of Dissolution of Group
    Not Applicable.
    Item 10.
    Certification
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

    Exhibits     Exhibit

    99.1                  Joint Filing Agreement by and among the Reporting Persons.



    SIGNATURE
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
    January 30, 2023


    LIND GLOBAL FUND II LP
       
    By:
     
    Lind Global Partners II LLC
     
     
    its General Partner
       
    By:
     
    /s/ Jeff Easton
    Name:
     
    Jeff Easton
    Title:
     
    Managing Member
     
    LIND GLOBAL PARTNERS II LLC
       
    By:
     
    /s/ Jeff Easton
    Name:
     
    Jeff Easton
    Title:
     
    Managing Member
     
    JEFF EASTON
     
    By:
     
    /s/ Jeff Easton


    Get the next $PBLA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PBLA

    DatePrice TargetRatingAnalyst
    6/28/2021$10.00Buy
    Roth Capital
    More analyst ratings

    $PBLA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by Panbela Therapeutics Inc.

      SC 13D - Panbela Therapeutics, Inc. (0001029125) (Subject)

      10/29/24 7:40:55 PM ET
      $PBLA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Panbela Therapeutics Inc. (Amendment)

      SC 13G/A - Panbela Therapeutics, Inc. (0001029125) (Subject)

      2/13/24 8:10:27 PM ET
      $PBLA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Panbela Therapeutics Inc. (Amendment)

      SC 13G/A - Panbela Therapeutics, Inc. (0001029125) (Subject)

      2/14/23 2:45:11 PM ET
      $PBLA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PBLA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Panbela Provides Business Update and Reports Q3 2024 Financial Results

      MINNEAPOLIS, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB:PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the quarter ended September 30, 2024. As previously announced, management is hosting an earnings call today at 4:30 p.m. ET. Q3 2024 and Recent Highlights: Up to $12.0 million financing commitment secured from strategic investor, Nant Capital.First patient enrolled in a Phase I dose escalation study to evaluate CPP-1X-S (eflornithine sachets) in STK11 mutant non-small cell lung cancer (NSCLC). Jennifer K. Simpson,

      11/14/24 4:10:36 PM ET
      $PBLA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Panbela to Host Third Quarter 2024 Earnings Conference Call on November 14, 2024

      MINNEAPOLIS, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB:PBLA), ("Panbela"), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on November 14, 2024, at 4:30 PM Eastern Time to discuss results for its third quarter ended September 30, 2024. Conference Call InformationToll Free: 877-545-0320International: 973-528-0002Participant Access Code: 370494Webcast Link: https://www.webcaster4.com/Webcast/Page/2556/51548 Conference Call Replay InformationToll Free: 877-481-4010International: 919-882-2331Replay Passcode: 51548Webcast Replay: https://www.

      10/31/24 8:00:00 AM ET
      $PBLA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • First Patient Enrolled in Phase I Program in STK11 Mutant Non-Small Cell Lung Cancer at Moffitt Cancer Center

      MINNEAPOLIS, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB:PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced the first patient enrolled in a Phase I dose escalation study to evaluate CPP-1X-S (eflornithine sachets) in STK11 mutant non-small cell lung cancer (NSCLC). The initial goal of the Phase I trial will be to determine the maximum tolerated dose of eflornithine in combination with the immune checkpoint inhibitor Keytruda, while evaluating efficacy and then moving into a Phase II efficacy trial. Data from the Phase I trial is expected by mid-2025, with a look to start

      9/24/24 8:00:00 AM ET
      $PBLA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PBLA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Large owner Nant Capital, Llc

      4 - Panbela Therapeutics, Inc. (0001029125) (Issuer)

      11/19/24 6:40:08 PM ET
      $PBLA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Nant Capital, Llc

      3 - Panbela Therapeutics, Inc. (0001029125) (Issuer)

      10/29/24 7:38:18 PM ET
      $PBLA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by V.P. of Finance & CFO Horvath Susan

      4 - Panbela Therapeutics, Inc. (0001029125) (Issuer)

      10/3/24 4:26:59 PM ET
      $PBLA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PBLA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $PBLA
    Financials

    Live finance-specific insights

    See more

    $PBLA
    SEC Filings

    See more
    • Roth Capital initiated coverage on Panbela Therapeutics with a new price target

      Roth Capital initiated coverage of Panbela Therapeutics with a rating of Buy and set a new price target of $10.00

      6/28/21 6:58:09 AM ET
      $PBLA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Maxim Group initiated coverage on Panbela Therapeutics with a new price target

      Maxim Group initiated coverage of Panbela Therapeutics with a rating of Buy and set a new price target of $8.00

      3/16/21 8:15:44 AM ET
      $PBLA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Maxim Group initiated coverage on Panbela Therapeutics with a new price target

      Maxim Group initiated coverage of Panbela Therapeutics with a rating of Buy and set a new price target of $8.00

      3/10/21 9:33:23 AM ET
      $PBLA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Panbela to Host Third Quarter 2024 Earnings Conference Call on November 14, 2024

      MINNEAPOLIS, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB:PBLA), ("Panbela"), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on November 14, 2024, at 4:30 PM Eastern Time to discuss results for its third quarter ended September 30, 2024. Conference Call InformationToll Free: 877-545-0320International: 973-528-0002Participant Access Code: 370494Webcast Link: https://www.webcaster4.com/Webcast/Page/2556/51548 Conference Call Replay InformationToll Free: 877-481-4010International: 919-882-2331Replay Passcode: 51548Webcast Replay: https://www.

      10/31/24 8:00:00 AM ET
      $PBLA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Panbela to Host Second Quarter 2024 Earnings Conference Call on Aug 13, 2024

      MINNEAPOLIS, July 30, 2024 (GLOBE NEWSWIRE) --  Panbela Therapeutics, Inc. (OTCQB:PBLA), ("Panbela"), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on Aug 13, 2024, at 4:30 PM Eastern Time to discuss results for its second quarter ended June 30, 2024. Conference Call Information Toll Free: 888-506-0062International: 973-528-0011Participant Access Code: 405072Webcast Link: https://www.webcaster4.com/Webcast/Page/2556/50956 Conference Call Replay Information Toll Free: 877-481-4010International: 919-882-2331Replay Passcode: 50956Webcast Replay: https://www.webc

      7/30/24 4:15:00 PM ET
      $PBLA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Panbela to Host First Quarter 2024 Earnings Conference Call on May 15, 2024

      MINNEAPOLIS, May 01, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB:PBLA), ("Panbela"), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on May 15, 2024, at 4:30 PM Eastern Time to discuss results for its first quarter ended March 31, 2024. Conference Call Information Toll Free: 877-545-0523International: 973-528-0016Participant Access Code: 234396Webcast Link: https://www.webcaster4.com/Webcast/Page/2556/50531 Conference Call Replay Information Toll Free: 877-481-4010International: 919-882-2331Replay Passcode: 50531Webcast Replay: https://www.webcas

      5/1/24 4:15:00 PM ET
      $PBLA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Panbela Therapeutics Inc. filed SEC Form 8-K: Leadership Update

      8-K - Panbela Therapeutics, Inc. (0001029125) (Filer)

      2/18/25 4:32:54 PM ET
      $PBLA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Panbela Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - Panbela Therapeutics, Inc. (0001029125) (Filer)

      2/4/25 4:02:40 PM ET
      $PBLA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Panbela Therapeutics Inc. filed SEC Form 8-K: Events That Accelerate or Increase a Direct Financial Obligation, Changes in Control of Registrant

      8-K - Panbela Therapeutics, Inc. (0001029125) (Filer)

      1/22/25 4:02:43 PM ET
      $PBLA
      Biotechnology: Pharmaceutical Preparations
      Health Care